Mitsubishi UFJ Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-74,256	Closed	-$153K	–	1140
2022 Q1	$153K	Buy	74,256 +5,116	+7%	+$13.8K	﹤0.01%	1094
2021 Q4	$281K	Buy	69,140 +8,292	+14%	+$37.7K	﹤0.01%	1022
2021 Q3	$315K	Hold	60,848	–	–	﹤0.01%	1006
2021 Q2	$259K	Sell	60,848 -16,072	-21%	-$78K	﹤0.01%	1056
2021 Q1	$408K	Buy	76,920 +26,013	+51%	+$149K	﹤0.01%	912
2020 Q4	$274K	Buy	+50,907	New	+$277K	﹤0.01%	919
2019 Q2	–	Sell	-28,621	Closed	-$123K	–	993
2019 Q1	$123K	Buy	28,621 +2,280	+9%	+$10.6K	﹤0.01%	855
2018 Q4	$141K	Buy	26,341 +15,361	+140%	+$113K	﹤0.01%	793
2018 Q3	$149K	Buy	+10,980	New	+$115K	﹤0.01%	805

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mitsubishi UFJ Asset Management's ADAP Position: Q2 2022 in Review

Mitsubishi UFJ Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q2 2022, closing a stake of 74,256 shares — an estimated $153K sold.

Mitsubishi UFJ Asset Management first reported a position in ADAP in Q3 2018 and held it in 9 quarters. The position peaked at $408K in Q1 2021. 77 funds tracked by Wall St. Rank hold ADAP as of Q2 2022.

Mitsubishi UFJ Asset Management reported no remaining Adaptimmune Therapeutics position as of Q2 2022 after selling out during the quarter.
Mitsubishi UFJ Asset Management sold 74,256 Adaptimmune Therapeutics shares in Q2 2022, an estimated $153K.
Mitsubishi UFJ Asset Management first reported a position in Adaptimmune Therapeutics in Q3 2018 and held it in 9 quarters.
Mitsubishi UFJ Asset Management's Adaptimmune Therapeutics position peaked at $408K in Q1 2021.
77 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2022.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2022, filed 4 Aug 2022.